The LEADER trial, with modified human GLP-1 receptor agonist liraglutide, included 23% of patients with a history of chronic kidney disease, and demonstrated a reduction in kidney failure, doubling of the serum creatinine, death from kidney disease, and a lowered risk of macroalbuminuria by 26% [35]. This evidence concerns the gene GLP1R and chronic kidney disease.